{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:35:35Z","timestamp":1792683335858,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02013-w","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:34:54Z","timestamp":1744194894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database"],"prefix":"10.1186","volume":"27","author":[{"given":"Jinming","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"1","key":"2013_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"Cancer J Clin"},{"issue":"6797","key":"2013_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature. 2000;406(6797):747\u201352.","journal-title":"Nature"},{"issue":"1","key":"2013_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jbi\/wbaa110","volume":"3","author":"KS Johnson","year":"2021","unstructured":"Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast cancer: A review for breast Radiologists[J]. J Breast Imaging. 2021;3(1):12\u201324.","journal-title":"J Breast Imaging"},{"key":"2013_CR4","doi-asserted-by":"crossref","unstructured":"Al-thoubaity FK. Molecular classification of breast cancer: A retrospective cohort study[J]. Annals of medicine and surgery (2012), 2020, 49: 44\u201348.","DOI":"10.1016\/j.amsu.2019.11.021"},{"issue":"1","key":"2013_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0378-1119(94)00866-Q","volume":"159","author":"PM Ravdin","year":"1995","unstructured":"Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers\u2013a review[J]. Gene. 1995;159(1):19\u201327.","journal-title":"Gene"},{"key":"2013_CR6","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer[J]. Volume 244. Science (New York, NY); 1989. pp. 707\u201312. 4905.","DOI":"10.1126\/science.2470152"},{"issue":"11","key":"2013_CR7","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s11864-023-01137-5","volume":"24","author":"M Stanowicka-grada","year":"2023","unstructured":"Stanowicka-grada M, Senkus E. Anti-HER2 drugs for the treatment of advanced HER2 positive breast Cancer[J]. Curr Treat Options Oncol. 2023;24(11):1633\u201350.","journal-title":"Curr Treat Options Oncol"},{"key":"2013_CR8","doi-asserted-by":"crossref","unstructured":"Eiger D, Franzoi MA, Pond\u00e9 N et al. Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials[J]. ESMO Open, 2020, 5(1).","DOI":"10.1136\/esmoopen-2019-000659"},{"issue":"32","key":"2013_CR9","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1200\/JCO.20.00184","volume":"38","author":"M Sawaki","year":"2020","unstructured":"Sawaki M, Taira N, Uemura Y, et al. Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-Positive early breast cancer in older Patients[J]. J Clin Oncology: Official J Am Soc Clin Oncol. 2020;38(32):3743\u201352.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"4","key":"2013_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol. 2020;21(4):519\u201330.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2013_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, Pertuzumab, and chemotherapy versus trastuzumab emtansine plus Pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol. 2018;19(1):115\u201326.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2013_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G Von Minckwitz","year":"2017","unstructured":"Von Minckwitz G, Procter M, De Azambuja E, et al. Adjuvant Pertuzumab and trastuzumab in early HER2-Positive breast Cancer[J]. N Engl J Med. 2017;377(2):122\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"2013_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, IM Y H, et al. 5-year analysis of neoadjuvant Pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol. 2016;17(6):791\u2013800.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2013_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","volume":"183","author":"MD Hackshaw","year":"2020","unstructured":"Hackshaw MD, Danysh HE, Singh J, et al. Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer[J]. Breast Cancer Res Treat. 2020;183(1):23\u201339.","journal-title":"Breast Cancer Res Treat"},{"key":"2013_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fphar.2017.00367","volume":"8","author":"F Paech","year":"2017","unstructured":"Paech F, Bouitbir J, Kr\u00e4henb\u00fchl S. Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and Inhibition of Glycolysis[J]. Front Pharmacol. 2017;8:367.","journal-title":"Front Pharmacol"},{"key":"2013_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fonc.2020.00271","volume":"10","author":"Y Li","year":"2020","unstructured":"Li Y, Gong C, Lu Q, et al. Real-World data of triplet combination of trastuzumab, lapatinib, and chemotherapy in HER2-Positive metastatic breast cancer: A multicenter retrospective Study[J]. Front Oncol. 2020;10:271.","journal-title":"Front Oncol"},{"key":"2013_CR17","doi-asserted-by":"publisher","first-page":"1017889","DOI":"10.3389\/fphar.2022.1017889","volume":"13","author":"P Ma","year":"2022","unstructured":"Ma P, Pan X, Liu R, et al. Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)[J]. Front Pharmacol. 2022;13:1017889.","journal-title":"Front Pharmacol"},{"issue":"24","key":"2013_CR18","first-page":"4728","volume":"40","author":"J Liu","year":"2015","unstructured":"Liu J, Xie YM, Gai GZ, et al. [Application analysis of adverse drug reaction terminology WHOART and MedDRA][J]. Zhongguo Zhong Yao Za zhi\u2009=\u2009zhongguo Zhongyao Zazhi\u2009=\u2009China. J Chin Materia Med. 2015;40(24):4728\u201333.","journal-title":"J Chin Materia Med"},{"issue":"8","key":"2013_CR19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/14740338.2023.2204228","volume":"22","author":"P Ma","year":"2023","unstructured":"Ma P, Tian H, SHI Q, et al. High risks adverse events associated with trastuzumab emtansine and trastuzumab Deruxtecan for the treatment of HER2-positive\/mutated malignancies: a pharmacovigilance study based on the FAERS database[J]. Exp Opin Drug Saf. 2023;22(8):685\u201396.","journal-title":"Exp Opin Drug Saf"},{"issue":"6","key":"2013_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting[J]. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2013_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1574886313666181026100000","volume":"14","author":"V Subeesh","year":"2019","unstructured":"Subeesh V, Maheswari E, SINGH H, et al. Novel adverse events of Iloperidone: A disproportionality analysis in US food and drug administration adverse event reporting system (FAERS) Database[J]. Curr Drug Saf. 2019;14(1):21\u20136.","journal-title":"Curr Drug Saf"},{"issue":"6","key":"2013_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019neill R T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database[J]. Drug Saf. 2002;25(6):381\u201392.","journal-title":"Drug Saf"},{"issue":"4","key":"2013_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A bayesian neural network method for adverse drug reaction signal generation[J]. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2013_CR24","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.esmoop.2021.100315","volume":"6","author":"NE Omar","year":"2021","unstructured":"Omar NE, Fahmy Soliman AI, Eshra M, et al. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA adverse event reporting system (FAERS)[J]. ESMO Open. 2021;6(6):100315.","journal-title":"ESMO Open"},{"issue":"1","key":"2013_CR25","doi-asserted-by":"publisher","first-page":"11955","DOI":"10.1038\/s41598-020-68906-2","volume":"10","author":"XF Jiao","year":"2020","unstructured":"Jiao XF, Li HL, Jiao XY, et al. Ovary and uterus related adverse events associated with Statin use: an analysis of the FDA adverse event reporting System[J]. Sci Rep. 2020;10(1):11955.","journal-title":"Sci Rep"},{"issue":"12","key":"2013_CR26","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2022.2078301","volume":"21","author":"X Tian","year":"2022","unstructured":"Tian X, Zheng S, Wang J, et al. Cardiac disorder-related adverse events for Aryl hydrocarbon receptor agonists: a safety review[J]. Exp Opin Drug Saf. 2022;21(12):1505\u201310.","journal-title":"Exp Opin Drug Saf"},{"issue":"2","key":"2013_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/cpt.3098","volume":"115","author":"X Li","year":"2024","unstructured":"Li X, Zhang L, Hu S, et al. Postmarketing safety of sacituzumab Govitecan: A pharmacovigilance study based on the FDA adverse event reporting System[J]. Clin Pharmacol Ther. 2024;115(2):256\u201368.","journal-title":"Clin Pharmacol Ther"},{"key":"2013_CR28","doi-asserted-by":"crossref","unstructured":"Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer-Epidemiology, classification, pathogenesis and treatment (Review of Literature)[J]. Cancers, 2022, 14(10).","DOI":"10.3390\/cancers14102569"},{"key":"2013_CR29","doi-asserted-by":"publisher","first-page":"1078191","DOI":"10.3389\/fpubh.2022.1078191","volume":"10","author":"L Lv","year":"2022","unstructured":"Lv L, Zhao B, Kang J, et al. Trend of disease burden and risk factors of breast cancer in developing countries and territories, from 1990 to 2019: results from the global burden of disease study 2019[J]. Front Public Health. 2022;10:1078191.","journal-title":"Front Public Health"},{"key":"2013_CR30","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3389\/fonc.2020.00864","volume":"10","author":"S Nardin","year":"2020","unstructured":"Nardin S, Mora E, Varughese FM, et al. Breast cancer survivorship, quality of life, and late Toxicities[J]. Front Oncol. 2020;10:864.","journal-title":"Front Oncol"},{"issue":"11","key":"2013_CR31","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1470-2045(12)70425-4","volume":"13","author":"Collaborative group on hormonal factors in breast C","year":"2012","unstructured":"Collaborative group on hormonal factors in breast C. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies[J]. Lancet Oncol. 2012;13(11):1141\u201351.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2013_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00280-024-04707-y","volume":"94","author":"X Luo","year":"2024","unstructured":"Luo X, Wang N, Xing Y, et al. Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients[J]. Cancer Chemother Pharmacol. 2024;94(5):721\u201332.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2013_CR33","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/14712598.2017.1282944","volume":"17","author":"L Gerratana","year":"2017","unstructured":"Gerratana L, Bonotto M, Bozza C, et al. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle[J]. Expert Opin Biol Ther. 2017;17(3):365\u201374.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"2013_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/CCO.0000000000000656","volume":"32","author":"E Nicol\u00f2","year":"2020","unstructured":"Nicol\u00f2 E, Zagami P. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?[J]. Curr Opin Oncol. 2020;32(5):494\u2013502.","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"2013_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok M, Joensuu H, Isola J. Trastuzumab Emtansine: mechanisms of action and drug resistance[J]. Breast cancer Research: BCR. 2014;16(2):209.","journal-title":"Breast cancer Research: BCR"},{"issue":"20","key":"2013_CR36","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1[J]. Clin cancer Research: Official J Am Association Cancer Res. 2016;22(20):5097\u2013108.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"5","key":"2013_CR37","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Trastuzumab Deruxtecan: first Approval[J]. Drugs. 2020;80(5):501\u20138.","journal-title":"Drugs"},{"issue":"7","key":"2013_CR38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40265-013-0050-2","volume":"73","author":"A Ballantyne","year":"2013","unstructured":"Ballantyne A, Dhillon S. Trastuzumab Emtansine: first global approval[J]. Drugs. 2013;73(7):755\u201365.","journal-title":"Drugs"},{"issue":"26","key":"2013_CR39","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. N Engl J Med. 2006;355(26):2733\u201343.","journal-title":"N Engl J Med"},{"key":"2013_CR40","doi-asserted-by":"crossref","unstructured":"Voigtlaender M, schneider-merck T, Trepel M. Lapatinib[J]. Recent results in cancer research fortschritte der krebsforschung progres Dans Les recherches Sur Le cancer, 2018, 211: 19\u201344.","DOI":"10.1007\/978-3-319-91442-8_2"},{"issue":"5","key":"2013_CR41","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-20-2701","volume":"27","author":"M Shah","year":"2021","unstructured":"Shah M, Wedam S, Cheng J, et al. FDA approval summary: Tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast Cancer[J]. Clin cancer Research: Official J Am Association Cancer Res. 2021;27(5):1220\u20136.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"2","key":"2013_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40261-018-0741-2","volume":"39","author":"S Dhillon","year":"2019","unstructured":"Dhillon S. Neratinib in Early-Stage breast cancer: A profile of its use in the EU[J]. Clin Drug Investig. 2019;39(2):221\u20139.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"2013_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3892\/etm.2021.11037","volume":"23","author":"G Iancu","year":"2022","unstructured":"Iancu G, Serban D, Badiu CD, et al. Tyrosine kinase inhibitors in breast cancer (Review)[J]. Experimental Therapeutic Med. 2022;23(2):114.","journal-title":"Experimental Therapeutic Med"},{"issue":"6","key":"2013_CR44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2217\/fon.12.66","volume":"8","author":"S L\u00f3pez-Tarruella","year":"2012","unstructured":"L\u00f3pez-Tarruella S, Jerez Y, M\u00e1rquez-Rodas I, et al. Neratinib (HKI-272) in the treatment of breast cancer[J]. Future Oncol (London England). 2012;8(6):671\u201381.","journal-title":"Future Oncol (London England)"},{"issue":"7","key":"2013_CR45","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2217\/fon-2019-0719","volume":"16","author":"A Nasrazadani","year":"2020","unstructured":"Nasrazadani A, Brufsky A. Neratinib: the emergence of a new player in the management of HER2\u2009+\u2009breast cancer brain metastasis[J]. Future Oncol (London England). 2020;16(7):247\u201354.","journal-title":"Future Oncol (London England)"},{"issue":"15","key":"2013_CR46","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-17-3628","volume":"24","author":"H Singh","year":"2018","unstructured":"Singh H, Walker AJ, Amiri-kordestani L, et al. U.S. Food and drug administration approval: neratinib for the extended adjuvant treatment of Early-Stage HER2-Positive breast Cancer[J]. Clin cancer Research: Official J Am Association Cancer Res. 2018;24(15):3486\u201391.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"17","key":"2013_CR47","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.7150\/jca.86746","volume":"14","author":"F Liu","year":"2023","unstructured":"Liu F, Yin G, Xue S, et al. Adverse event profile differences between trastuzumab emtansine and trastuzumab Deruxtecan: A Real-world, pharmacovigilance Study[J]. J Cancer. 2023;14(17):3275\u201384.","journal-title":"J Cancer"},{"issue":"2","key":"2013_CR48","first-page":"190","volume":"17","author":"J Huszno","year":"2013","unstructured":"Huszno J, Le\u015b D, Sarzyczny-S\u0142ota D, et al. Cardiac side effects of trastuzumab in breast cancer patients - single centere experiences[J]. Contemp Oncol (Poznan Poland). 2013;17(2):190\u20135.","journal-title":"Contemp Oncol (Poznan Poland)"},{"key":"2013_CR49","doi-asserted-by":"publisher","first-page":"821663","DOI":"10.3389\/fcvm.2021.821663","volume":"8","author":"M Lin","year":"2021","unstructured":"Lin M, Xiong W, Wang S, et al. The research progress of Trastuzumab-Induced cardiotoxicity in HER-2-Positive breast cancer Treatment[J]. Front Cardiovasc Med. 2021;8:821663.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"2013_CR50","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1081\/CNV-200032951","volume":"22","author":"H Safran","year":"2004","unstructured":"Safran H, Dipetrillo T, Nadeem A, et al. Trastuzumab, Paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study[J]. Cancer Invest. 2004;22(5):670\u20137.","journal-title":"Cancer Invest"},{"issue":"21","key":"2013_CR51","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1111\/bph.13643","volume":"174","author":"BT Nemeth","year":"2017","unstructured":"Nemeth BT, Varga ZV, Wu WJ, et al. Trastuzumab cardiotoxicity: from clinical trials to experimental studies[J]. Br J Pharmacol. 2017;174(21):3727\u201348.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"2013_CR52","doi-asserted-by":"publisher","first-page":"ofy255","DOI":"10.1093\/ofid\/ofy255","volume":"5","author":"J Nordvig","year":"2018","unstructured":"Nordvig J, Aagaard T, Daugaard G, et al. Febrile neutropenia and Long-term risk of infection among patients treated with chemotherapy for malignant Diseases[J]. Open Forum Infect Dis. 2018;5(10):ofy255.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2013_CR53","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/s12885-021-08162-3","volume":"21","author":"A Andrikopoulou","year":"2021","unstructured":"Andrikopoulou A, Apostolidou K, Chatzinikolaou S, et al. Trastuzumab administration during pregnancy: an update[J]. BMC Cancer. 2021;21(1):463.","journal-title":"BMC Cancer"},{"issue":"1","key":"2013_CR54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12905-021-01301-9","volume":"21","author":"LY Xia","year":"2021","unstructured":"Xia LY, Hu QL, Zhou Q. Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis[J]. BMC Womens Health. 2021;21(1):169.","journal-title":"BMC Womens Health"},{"issue":"3","key":"2013_CR55","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/1535-7163.MCT-15-0580","volume":"15","author":"H Yan","year":"2016","unstructured":"Yan H, Endo Y, Shen Y, et al. Ado-Trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce Hepatotoxicity[J]. Mol Cancer Ther. 2016;15(3):480\u201390.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2013_CR56","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.ejso.2013.09.015","volume":"40","author":"G Morris-Stiff","year":"2014","unstructured":"Morris-Stiff G, White AD, Gomez D, et al. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases[J]. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2014;40(8):1016\u201320.","journal-title":"Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol"},{"issue":"7","key":"2013_CR57","first-page":"23","volume":"12","author":"P Milam","year":"2019","unstructured":"Milam P, Berger M, Ramaswamy B, et al. Spider telangiectases and palmar erythema as harbingers of structural liver changes in three breast cancer patients on Ado-trastuzumab Emtansine[J]. J Clin Aesthetic Dermatol. 2019;12(7):23\u20136.","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"15","key":"2013_CR58","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s40265-017-0811-4","volume":"77","author":"ED Deeks","year":"2017","unstructured":"Deeks ED, Neratinib. First global Approval[J]. Drugs. 2017;77(15):1695\u2013704.","journal-title":"Drugs"},{"issue":"6","key":"2013_CR59","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00280-013-2262-2","volume":"72","author":"RC Jankowitz","year":"2013","unstructured":"Jankowitz RC, Abraham J, Tan AR, et al. Safety and efficacy of neratinib in combination with weekly Paclitaxel and trastuzumab in women with metastatic HER2\u2013positive breast cancer: an NSABP foundation research program phase I study[J]. Cancer Chemother Pharmacol. 2013;72(6):1205\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2013_CR60","doi-asserted-by":"crossref","unstructured":"Guo L, Shao W, Zhou C et al. Neratinib for HER2-positive breast cancer with an overlooked option[J]. Molecular medicine (Cambridge, Mass), 2023, 29(1): 134.","DOI":"10.1186\/s10020-023-00736-0"},{"key":"2013_CR61","doi-asserted-by":"publisher","first-page":"1425171","DOI":"10.3389\/fphar.2024.1425171","volume":"15","author":"Y Fan","year":"2024","unstructured":"Fan Y, Wu T, Xu P, et al. Neratinib safety evaluation: real-world adverse event analysis from the FAERS database[J]. Front Pharmacol. 2024;15:1425171.","journal-title":"Front Pharmacol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02013-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02013-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02013-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T21:05:39Z","timestamp":1744232739000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-02013-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2013"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02013-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a medical research paper using a public database and it does not involve ethical issues.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}